PTP1B在心脏代谢障碍和内皮功能障碍中的作用
Mona A Sawali1, Muhammad Ammar Zahid1, Shahenda Salah Abdelsalam1
1Department of Pharmaceutical Sciences, College of Pharmacy, QU Health, Qatar University, Doha, Qatar.
Journal of drug targeting
|February 25, 2025
概括
蛋白氨酸酸酶1B (PTP1B) 在与代谢疾病和心血管疾病 (CVD) 相关的内皮功能障碍中至关重要. 抑制PTP1B提供了管理这些相互关联的条件的潜力,尽管目前的候选药物存在挑战.
科学领域:
- 生物化学 生物化学
- 心血管生物学 心血管生物学
- 代谢研究研究 代谢研究
背景情况:
- 心血管疾病 (CVD) 是全球主要的死亡原因.
- 内皮功能障碍是心血管事件的主要驱动因素.
- 蛋白氨酸酸酶1B (PTP1B) 通过代谢途径在内皮功能障碍中发挥关键作用.
研究的目的:
- 分析PTP1B在代谢性疾病中的作用及其与心血管疾病的联系.
- 检查开发PTP1B抑制剂的战略和挑战.
- 提供关于PTP1B在健康和疾病中的功能的深入审查.
主要方法:
- 关于PTP1B,代谢性疾病和心血管疾病的研究文献综述.
- 分析涉及PTP1B,胰岛素/瘦素信号传递和内质网膜应激的分子机制.
- 评估现有的PTP1B抑制剂及其临床试验进展情况.
主要成果:
- 通过损害胰岛素和瘦素信号传递,PTP1B有助于内皮功能障碍.
- PTP1B会加剧糖尿病和肥胖等代谢疾病.
- 由PTP1B诱导的内质网膜应激是内皮功能障碍的分子驱动因素.
结论:
- 抑制PTP1B是对心血管疾病和代谢障碍的有希望的治疗策略.
- 开发PTP1B抑制剂的挑战包括选择性和副作用.
- 准PTP1B可能会解决这些流行疾病背后的共同风险因素和机制.
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
41
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
41
cAMP-dependent Protein Kinase Pathways
6.1K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.1K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
128
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
128


